118 related articles for article (PubMed ID: 38556816)
21. Cell Counts, rather than Proportion, of CD8/PD-1 Tumor-Infiltrating Lymphocytes in a Tumor Microenvironment Associated with Pathological Characteristics of Chinese Invasive Ductal Breast Cancer.
Song Q; Shi F; Adair M; Chang H; Guan X; Zhao Y; Li Y; Wu G; Wu J
J Immunol Res; 2019; 2019():8505021. PubMed ID: 31049361
[TBL] [Abstract][Full Text] [Related]
22. CD45RO+TILs: cellular biomarkers for larynx squamous cell carcinoma outcome.
Mohammadi Y; Ahmadvand S; Mirtalebi M; Ashraf MJ; Khademi B; Ghaderi A
Braz J Otorhinolaryngol; 2022; 88 Suppl 4(Suppl 4):S133-S142. PubMed ID: 36319566
[TBL] [Abstract][Full Text] [Related]
23. Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ.
Beguinot M; Dauplat MM; Kwiatkowski F; Lebouedec G; Tixier L; Pomel C; Penault-Llorca F; Radosevic-Robin N
BMC Cancer; 2018 Feb; 18(1):129. PubMed ID: 29394917
[TBL] [Abstract][Full Text] [Related]
24. Touching tumour-infiltrating lymphocytes in low-risk ductal carcinoma in situ (DCIS) correlate with upgrading to high-grade DCIS.
Khoury T; Quinn M; Tian W; Yan L; Zhan H
Histopathology; 2022 Jan; 80(2):291-303. PubMed ID: 34379814
[TBL] [Abstract][Full Text] [Related]
25. Importance of CD45RO+ tumor-infiltrating lymphocytes in post-operative survival of breast cancer patients.
Ahmadvand S; Faghih Z; Montazer M; Safaei A; Mokhtari M; Jafari P; Talei AR; Tahmasebi S; Ghaderi A
Cell Oncol (Dordr); 2019 Jun; 42(3):343-356. PubMed ID: 30825183
[TBL] [Abstract][Full Text] [Related]
26. [Clinicopathologic observation of carcinomas arising in fibroepithelial neoplasms of the breast].
Yang G; Guo L; Jin H; Li J; Ding H
Zhonghua Bing Li Xue Za Zhi; 2014 Jul; 43(7):437-41. PubMed ID: 25327790
[TBL] [Abstract][Full Text] [Related]
27. Tumor Infiltrating Lymphocytes are Prognostic Factors and Can Be Markers of Sensitivity to Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma.
Suzuki H; Kawasaki Y; Miura M; Hatakeyama H; Shina K; Suzuki S; Yamada T; Suzuki M; Ito A; Omori Y
Asian Pac J Cancer Prev; 2022 Apr; 23(4):1271-1278. PubMed ID: 35485685
[TBL] [Abstract][Full Text] [Related]
28. [Clinicopathologic study of infiltrating epitheliosis of the breast].
Xu XL; Tu XY; Shui RH; Cheng YF; Yu BH; Yang WT
Zhonghua Bing Li Xue Za Zhi; 2017 Dec; 46(12):827-831. PubMed ID: 29224275
[No Abstract] [Full Text] [Related]
29. Prognostic Value of Tumor Infiltrating Lymphocytes in Locally Advanced HER2 Enriched Breast Cancer.
Saber MM; El Zawahry HM; Hilal AM; Abou-Bakr AA; Namour AE; Saber MM
Asian Pac J Cancer Prev; 2022 Feb; 23(2):553-560. PubMed ID: 35225468
[TBL] [Abstract][Full Text] [Related]
30. Novel pathological predictive factors for extranodal extension in oral squamous cell carcinoma: a retrospective cohort study based on tumor budding, desmoplastic reaction, tumor-infiltrating lymphocytes, and depth of invasion.
Noda Y; Ishida M; Ueno Y; Fujisawa T; Iwai H; Tsuta K
BMC Cancer; 2022 Apr; 22(1):402. PubMed ID: 35418058
[TBL] [Abstract][Full Text] [Related]
31. The immune microenvironment of breast ductal carcinoma in situ.
Thompson E; Taube JM; Elwood H; Sharma R; Meeker A; Warzecha HN; Argani P; Cimino-Mathews A; Emens LA
Mod Pathol; 2016 Mar; 29(3):249-58. PubMed ID: 26769139
[TBL] [Abstract][Full Text] [Related]
32. Uncovering PD-L1 and CD8
Chen J; Gu P; Wu H
Biomed Res Int; 2020; 2020():8164365. PubMed ID: 32884946
[TBL] [Abstract][Full Text] [Related]
33. Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: results of a pilot study.
Zeppellini A; Galimberti S; Leone BE; Pacifico C; Riva F; Cicchiello F; Capici S; Maggioni C; Sala L; Cazzaniga ME
BMC Cancer; 2021 Mar; 21(1):260. PubMed ID: 33691674
[TBL] [Abstract][Full Text] [Related]
34. [Pathological features and immune microenvironment in HER-2 intratumoral heterogeneous breast cancers].
Yang YL; Song YM; Xue HQ; Sun H; Li YQ; Qian XL; Jiao J; Li KP; Zhang H; Guo XJ
Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):165-169. PubMed ID: 36781238
[No Abstract] [Full Text] [Related]
35. Tumor-infiltrating ICOS
Kajikawa H; Hirata M; Haruna M; Ueyama A; Hirose K; Kawashima A; Iwahori K; Matsunaga K; Toyosawa S; Uzawa N; Wada H
Anticancer Res; 2022 May; 42(5):2383-2393. PubMed ID: 35489733
[TBL] [Abstract][Full Text] [Related]
36. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.
Kim M; Chung YR; Kim HJ; Woo JW; Ahn S; Park SY
Breast Cancer Res; 2020 Mar; 22(1):32. PubMed ID: 32216826
[TBL] [Abstract][Full Text] [Related]
37. CD8+ TILS Expression in Invasive Breast Carcinoma (No Special Type).
Astuti A; Miskad UA; Arsyadi G; Zainuddin AA; Wahid S; Nelwan BJ
Asian Pac J Cancer Prev; 2022 May; 23(5):1813-1816. PubMed ID: 35633568
[TBL] [Abstract][Full Text] [Related]
38. Tumor infiltrative growth pattern correlates with the immune microenvironment and is an independent factor for lymph node metastasis and prognosis in stage T1 esophageal squamous cell carcinoma.
Zhao Y; Xu E; Yang X; Zhang Y; Chen H; Wang Y; Jin M
Virchows Arch; 2020 Sep; 477(3):401-408. PubMed ID: 32232560
[TBL] [Abstract][Full Text] [Related]
39. Increased HIF-1alpha expression in tumor cells and lymphocytes of tumor microenvironments predicts unfavorable survival in esophageal squamous cell carcinoma patients.
Zhang L; Ye SB; Li ZL; Ma G; Chen SP; He J; Liu WL; Xie D; Zeng YX; Li J
Int J Clin Exp Pathol; 2014; 7(7):3887-97. PubMed ID: 25120765
[TBL] [Abstract][Full Text] [Related]
40. Prognostic and Therapeutic Implications of Immune Classification by CD8
García-Marín R; Reda S; Riobello C; Cabal VN; Suárez-Fernández L; Vivanco B; Álvarez-Marcos C; López F; Llorente JL; Hermsen MA
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34203211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
